REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC
D. I. Yudin,
K. K. Laktionov,
R. A. Zukov,
I. L. Obraz,
D. V. Perunov,
M. M. Magamedova,
F. V. Moiseenko,
E. О. Elsakova,
A. V. Sultanbaev,
K. V. Menshikov,
M. A. Zafirova,
S. V. Gamayunov,
A. M. Abdelgafur,
V. V. Petkau,
V. M. Moiseenko https://doi.org/10.21518/ms2025-508
Abstract
Introduction. Atezolizumab, bevacizumab, and chemotherapy (ABCP) is a standard of care for advanced non-squamous NSCLC, including post-TKI patients with EGFR/ALK mutations. Real-world data on ABCP efficacy in Russia are limited.
Aim. To evaluate OS and PFS in real-world NSCLC patients who received ≥4 cycles of first-line ABCP followed by atezolizumab-bevacizumab (AB) maintenance.
Materials and methods. REACT is an observational, retrospective, multicenter study of adult patients with advanced NSCLC (diagnosed 2021–2023) who received ≥4 ABCP cycles and started AB maintenance. Key endpoints included ORR, PFS, and OS.
Results. Data from 108 patients were included: 78 patients (72.2%) received ABCP in first line (wild type) and 30 (27.8%) were post-TKI (EGFR/ALK+). Median age 57.6 years; 63.9% male. Baseline metastases: CNS (17.6%), liver (8.3%), bone (33.3%). ORR was 56.5% (59.0% first line); DCR 98.2%. Median PFS was 14.7 months (95% CI 12.4–23.9) in first line group and 9.3 months (95% CI 7.4–14.6) in post-TKI group. Median OS was 34.4 months (95% CI 21.8–NR) in first line group and 24.2 months (95% CI 21.8–NR) post-TKI. 2-year OS rates were 52.7% and 54.4%, respectively. High tumor burden (≥3 sites), large sum of longest diameters, and bone metastases were negative prognostic factors. Age, sex, smoking, and PD-L1 status had no significant impact.
Conclusion. In this cohort, the ABCP regimen was highly effective. Results align with IMpower150 trial for post-TKI patients and demonstrate prolonged survival in the first-line setting.
Supporting agencies: This work was supported by “Roche-Moscow” JSC. The authors thank the patients and their families.
About the Authors
D. I. Yudin
Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Denis I. Yudin - Cand. Sci. (Med.), Senior Researcher, Department of Antitumor Drug Therapy No. 3, Drug Treatment Department, Blokhin National Medical Research Center of Oncology.
24, Kashirskoye Shosse, Moscow, 115478
K. K. Laktionov
Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Konstantin K. Laktionov - Dr. Sci. (Med.), First Deputy Director, Head of the Department of Antitumor Drug Therapy No. 3, Department of Drug Treatment, Blokhin National Medical Research Center of Oncology; Professor of the Department of Oncology and Radiation Therapy Institute of Surgery, Pirogov Russian National Research Medical University.
24, Kashirskoye Shosse, Moscow, 115478; 1, Ostrovityanov St., Moscow, 117997
R. A. Zukov
Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky; Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
Russian Federation
Russian Federation
Ruslan A. Zukov - Dr. Sci. (Med.), Professor, Chief Physician, Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky; Head of the Department of Oncology and Radiation Therapy with a Postgraduate Education Course, Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky.
16, 1st Smolenskaya St., Krasnoyarsk, 660133; 1, Partizana Zheleznyaka St., Krasnoyarsk, 660022
I. L. Obraz
Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky
Russian Federation
Russian Federation
Irina L. Obraz - Oncologist, Head of Day-Patient Department No. 2 for Antitumor Drug Therapy, Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky.
16, 1st Smolenskaya St., Krasnoyarsk, 660133
D. V. Perunov
Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky
Russian Federation
Russian Federation
Dmitry V. Perunov - Oncologist, Department of Hematology and Antitumor Drug Therapy, Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky.
167, 1st Maya St., Krasnodar, 350901
M. M. Magamedova
Republican Oncological Dispensary
Russian Federation
Russian Federation
Maryam M. Magamedova - Oncologist, Republican Oncological Dispensary.
24/2, Gaidar Gadzhiev St., Makhachkala, 367027
F. V. Moiseenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov; North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Fedor V. Moiseenko - Dr. Sci. (Med.), Head of the Chemotherapy Department, Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov; Researcher, Scientific Department of Innovative Methods in Therapeutic Oncology and Rehabilitation, North-Western State Medical University named after I.I. Mechnikov.
68A, Lit. A, Leningradskaya St., Pesochnyy Settlement, St Petersburg, 197758; 41, Kirochnaya St., St Petersburg, 191015
E. О. Elsakova
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov
Russian Federation
Russian Federation
Ekaterina О. Elsakova - Oncologist, Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov.
68A, Lit. A, Leningradskaya St., Pesochnyy Settlement, St Petersburg, 197758
A. V. Sultanbaev
Republican Clinical Oncology Dispensary; Bashkir State Medical University; Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Russian Federation
Russian Federation
Alexander V. Sultanbaev - Cand. Sci. (Med.), Associate Professor Department of Pedagogy and Psychology, Bashkir State Medical University; Head of the Department of Antitumor Drug Therapy, Republican Clinical Oncology Dispensary; Senior Researcher, Laboratory of Inflammation Immunology, Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences.
3, Lenin St., Ufa, 450008; 73/1, Oktyabrya Ave., Ufa, 450054; 106, Pervomayskaya St., Ekaterinburg, 620049
K. V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Russian Federation
Russian Federation
Konstantin V. Menshikov - Cand. Sci. (Med.), Associate Professor Department of Oncology and Clinical Morphology, Bashkir State Medical University; Oncologist of the Chemotherapy Department, Republican Clinical Oncology Dispensary.
3, Lenin St., Ufa, 450008; 73/1, Oktyabrya Ave., Ufa, 450054
M. A. Zafirova
Sverdlovsk Regional Oncological Dispensary
Russian Federation
Russian Federation
Marina A. Zafirova - Head of the Chemotherapy Service, Sverdlovsk Regional Oncological Dispensary.
29, Sobolev St., Ekaterinburg, 620036
S. V. Gamayunov
Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”; Privolzhsky Research Medical University
Russian Federation
Russian Federation
Sergey V. Gamayunov - Dr. Sci. (Med.), Chief Physician, Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”; Professor of the Department of Oncology, Radiology and Radiation Therapy named after N. E. Yakhontov, Privolzhsky Research Medical University.
11/1, Delovaya St., Nizhny Novgorod, 603163; 10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950
A. M. Abdelgafur
Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”
Russian Federation
Russian Federation
Ahmed M. Abdelgafur - Head of Department, Oncologist of the Highest Qualification Category, Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”.
11/1, Delovaya St., Nizhny Novgorod, 603163
V. V. Petkau
Sverdlovsk Regional Oncological Dispensary
Russian Federation
Russian Federation
Vladislav V. Petkau - Deputy Chief Physician for Drug Therapy, Sverdlovsk Regional Oncological Dispensary.
29, Sobolev St., Ekaterinburg, 620036
V. M. Moiseenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov; North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Vladimir M. Moiseenko - Corr. Member RAS, Dr. Sci. (Med.), Professor, Honored Doctor of the Russian Federation, Director, Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov.
68A, Lit. A, Leningradskaya St., Pesochnyy Settlement, St Petersburg, 197758
References
1. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019;94(8):1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.013.
2. Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992–1998. https://doi.org/10.1200/JCO.22.01989.
3. Laktionov K, Smolin A, Stroyakovskiy D, Moiseenko V, Dvorkin M, Andabekov T et al. Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer. Eur J Cancer. 2025;217:115255. https://doi.org/10.1016/j.ejca.2025.115255.
4. Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023;41(6):1200–1212. https://doi.org/10.1200/JCO.22.01503.
5. Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024;211:114296. https://doi.org/10.1016/j.ejca.2024.114296.
6. Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. J Thorac Oncol. 2025;20(1):76–93. https://doi.org/10.1016/j.jtho.2024.09.1381.
7. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. https://doi.org/10.1056/NEJMoa1716948.
8. Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909–1924. https://doi.org/10.1016/j.jtho.2021.07.009.
9. Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. https://doi.org/10.1038/ncomms12624.
10. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. https://doi.org/10.1016/j.ctrv.2020.102017.
11. Лактионов КК, Артамонова ЕВ, Борисова ТН, Бредер ВВ, Бычков ЮМ, Владимирова ЛЮ и др. Злокачественное новообразование бронхов и легкого: клинические рекомендации. 2022. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/30_4.
12. Laktionov K, Artamonova E, Breder V, Gorbunova V, Demidova I, Dengina N et al Non-small cell lung cancer. Malignant Tumours. 2024;14(3s2-1):65–104. (In Russ.) https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-04.
13. Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y et al. Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nat Med. 2025;31(7):2375–2384. https://doi.org/10.1038/s41591-025-03658-y.
14. Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K et al. Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024;10(3):315–324. https://doi.org/10.1001/jamaoncol.2023.5258.
15. Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F et al. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2022;17(2):309–323. https://doi.org/10.1016/j.jtho.2021.09.014.
16. Jotte RM, Batus M, Bernicker E, Copur MS, Kirshner E, Koh HA et al. IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease. J Clin Oncol. 2020;38(15 Suppl.):e21637. https://doi.org/10.1200/JCO.2020.38.15_suppl.e21637.
17. Rothenstein J, Spira A, Velcheti V, Natale R, Kozloff M, Kosty M et al. P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab. J Thor Oncol. 2018;13(10 Suppl.):S495). https://doi.org/10.1016/j.jtho.2018.08.639.
18. Reck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D et al. IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. Ann Oncol. 2018;29(Suppl. 8):VIII498–VIII499. https://doi.org/10.1093/annonc/mdy292.009.
19. Cappuzzo F, Reck M, Socinski MA, Mok TS, Jotte RM, Finleyet GG al. IMpower150: Exploratory analysis of brain metastases development. J Clin Oncol. 2020;38(15 Suppl.):9587. https://doi.org/10.1200/JCO.2020.38.15_suppl.9587.
Review
For citations:
Yudin DI, Laktionov KK, Zukov RA, Obraz IL, Perunov DV, Magamedova MM, Moiseenko FV, Elsakova EО, Sultanbaev AV, Menshikov KV, Zafirova MA, Gamayunov SV, Abdelgafur AM, Petkau VV, Moiseenko VM. REACT: Real-world survival outcomes with atezolizumab, bevacizumab, and chemotherapy for treatment of advanced non-squamous NSCLC. Meditsinskiy sovet = Medical Council. 2025;(21):96-108. (In Russ.) https://doi.org/10.21518/ms2025-508
Views:
33
Email this article 